Physician profile
Robert L Marshall
NPI 1891991881
$562.28
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2022: $38.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113.05 | 2019 | |
| Amgen INC. | $110.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $64.68 | 2019 | |
| Biogen, INC. | $49.88 | 2019 | |
| Genzyme Corporation | $48.75 | 2019 | |
| Dexcom, INC. | $38.26 | 2022 | |
| Medexus Pharma, INC. | $36.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.92 | 2019 | |
| Ucb, INC. | $27.72 | 2019 | |
| Glaxosmithkline, LLC. | $20.02 | 2019 | |
| Aquestive Therapeutics, INC. | $17.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.